Is 8037.HK overvalued or undervalued?

8037.HK currently has a P/E ratio of -14.31. Relative to the sector average of 15.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy China Biotech Services Holdings Limited stock?

China Biotech Services Holdings Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 8037.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 8037.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 8037.HK to protect their purchasing power. Because 8037.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 8037.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 8037.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 8037.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks8037.HK

China Biotech Services Holdings Limited

HK$0.51-HK$0.02-3.81%

HKSE / HKD

Market cap

HK$493M

P/E

-14.3

EPS (TTM)

HK$-0.00

Dividend yield

0.00%

Beta

-0.67

1Y return

-49.50%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$80M2021

$237M2022

$27M2023

$9M2024

$9M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity2.13High
Current ratio0.99
Cash ratio0.34
Net margin-37.8%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

8037.HK-14.3
Healthcare sector median15.8
S&P 50022.0

Trades about 191% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.14
Price to book2.28
EPS (TTM)HK$-0.00
Payout ratio0%
FCF yield-25.50%

Range & risk

HK$0.30HK$1.04

Trading in the lower third of its 52-week band

Beta-0.67

Profile

What China Biotech Services Holdings Limited actually does

Established in 1996 and based in Causeway Bay, Hong Kong, China Biotech Services Holdings Limited functions as an investment holding company. Its core business involves providing medical laboratory testing and health check services throughout mainland China and Hong Kong. The company organizes its varied operations into five main divisions: Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, and Insurance Brokerage, in addition to other undertakings. Its comprehensive activities include the research, development, manufacturing, and sale of both health-related and pharmaceutical products. The company also offers specialized medical services, such as tumor immune cell therapy, immune cell storage, and health management programs, alongside coordinating healthcare providers. Furthermore, it participates in financial services like securities trading, money lending, and providing insurance brokerage. Its commercial ventures also extend to marketing and distributing a range of wellness products, including health supplements, slimming aids, traditional Chinese medicines, and beauty products, as well as trading pharmaceutical intermediates. Property investment and logistics services round out its operational scope. The company transitioned to its current name in November 2017, having previously been known as Rui Kang Pharmaceutical Group Investments Limited.

CEO

Xiaolin Liu

Employees

166

Headquarters

Hong Kong

Founded

2004-06-17

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 8037.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

8037.HK has a beta of -0.67, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

China Biotech Services Holdings Limited